Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction of outcomes for high-count monoclonal B lymphocytosis

In this week's episode, we’ll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and immunogenetic signatures can be used in the prediction of outcomes for high-count monoclonal B lymphocytosis.

Featured Articles: 

• Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update 
• Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature 
• High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: The HUNT study